New therapeutic approaches and prognostic factors in chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 625-628

  Saglio, Giuseppe ^a   Ulisciani, Stefano ^a   Bosa, Marco ^a   Cilloni, Daniela ^a   Rege Cambrin, Giovanna ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

BCR ABL; CML; Imatinib; Ph chromosome; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFORMATION; GENOMIC INSTABILITY; HUMAN; MOLECULAR CLONING; PATIENT COMPLIANCE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PYRIMIDINES;

EID: 42049122204     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801896210     Document Type: Conference Paper

References (15)

1. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarijan, H. M. and Gattermann, N. (2006) IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, pp. 2408-2417.
2. Baccarani, M., Saglio, G., Goldman, J., Hochaus, A., Simonsson, B. and Appelbaum, F. (2006) European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, pp. 1809-1820.
3. Picard, S., Titier, K., Etienne, G., Teichet, E., Ducint, D. and Bernard, M. A. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109, pp. 3496-3499.
4. White, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A. and Zrim, S. (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110, pp. 4064-4072.
5. Apperley, J. F. (2007) Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol, 8, pp. 1018-1029.
6. Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. and Griffin, J. D. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer, 7, pp. 345-356.
7. Cortes, J. and O'Dwyer, M. E. (2004) Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am, 18, pp. 671-684.
8. Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R. and Aggarwal, B. B. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res, 64, pp. 672-677.
9. Penserga, E. T. and Skorski, T. (2007) Fusion tyrosine kinases: A result and cause of genomic instability. Oncogene, 26, pp. 11-20.
10. Kreil, S., Pfirrmann, M., Haferlach, C., Waghorn, K., Chase, A. and Hehlmann, R. (2007) German Chronic Myelogenous Leukemia (CML) Study Group. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood, 110, pp. 1283-1290.
11. Hughes, T., Deininger, M., Hochhaus, A., Brandford, S., Radich, J. and Kaede, J. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, pp. 28-37.
12. Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipron, J. H., Apperley, J. F. and Druker, B. J. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109, pp. 2303-2309.
13. Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G. and Palandri, F. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110, pp. 3540-3546.
14. Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M. and Paquette, R. L. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest, 117, pp. 2562-2569.
15. Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Palandri, F. and Giannoulia, P. (2007) Philadelphia chromosome-positive leukemia patients who harbor imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood, 110, p. 101a.